Eplerenone

Generic Name: Eplerenone

Brand Names: Inspra

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₃₀O_₆

CAS Number: 107724-20-9

Unique Ingredient Identifier: 6995V82D0B

Background: Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. Eplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and androgen receptors.

Indication: For improvement of survival of stable patients with left ventricular systolic dysfunction (ejection fraction <40%) and clinical evidence of congestive heart failure after an acute myocardial infarction.

Associated Conditions: Hypertension, LVEF <40% Congestive heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class II)

Associated Therapies: -

Clinical Trials

Cardiometabolic Effects of Eplerenone in HIV Infection

Phase 2

Terminated

Conditions: Hepatic Steatosis
Cardiac Steatosis

Interventions: Drug: Inspra /Eplerenone

First Posted Date: 2015-12-14

Last Posted Date: 2018-07-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 5

Registration Number: NCT02629094

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism

Phase 2

Completed

Conditions: Primary Hyperparathyroidism

Interventions: Drug: Placebo
Drug: amiloride
Drug: eplerenone
Drug: Cinacalcet

First Posted Date: 2015-08-17

Last Posted Date: 2023-05-03

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 69

Registration Number: NCT02525796

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Eplerenone in Patients Undergoing REnal Transplant (EPURE TRANSPLANT)

Phase 3

Active, not recruiting

Conditions: End-stage Renal Disease

Interventions: Drug: Placebo
Drug: Eplerenone

First Posted Date: 2015-07-07

Last Posted Date: 2023-06-18

Lead Sponsor: Central Hospital, Nancy, France

Target Recruit Count: 132

Registration Number: NCT02490904

Locations: 🇫🇷
CHU Dijon- Hôpital Bocage Central, Dijon, France
🇫🇷
CHRU Besançon, Besancon, France
🇫🇷
CHU Brest, Brest, France

and more 4 locations

Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy

Phase 3

Completed

Conditions: Duchenne Muscular Dystrophy

Interventions: Drug: Eplerenone
Drug: Spironolactone

First Posted Date: 2015-02-03

Last Posted Date: 2019-10-07

Lead Sponsor: Ohio State University

Target Recruit Count: 52

Registration Number: NCT02354352

Locations: 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸
The Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸
Mattel Children's Hospital and David Geffen School of Medicine at UCLA, Los Angeles, California, United States

and more 3 locations

A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Subjects

Phase 2

Completed

Conditions: Essential Hypertension

Interventions: Drug: CS-3150
Drug: placebo
Drug: eplerenone

First Posted Date: 2015-01-26

Last Posted Date: 2019-10-08

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 426

Registration Number: NCT02345044

Eplerenone in the Management of Abdominal Aortic Aneurysms

Phase 4

Conditions: Aortic Aneurysm, Abdominal

Interventions: Drug: Eplerenone

First Posted Date: 2015-01-26

Last Posted Date: 2016-01-15

Lead Sponsor: Bayside Health

Target Recruit Count: 172

Registration Number: NCT02345590

Locations: 🇦🇺
Baker IDI, Melbourne, Victoria, Australia
🇦🇺
Heart Centre, Alfred Health, Melbourne, Victoria, Australia

A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy

Phase 2

Conditions: Central Serous Chorioretinopathy

Interventions: Drug: Eplerenone
Drug: Maltodextrin

First Posted Date: 2014-08-13

Last Posted Date: 2014-08-13

Lead Sponsor: Prim. Prof. Dr. Oliver Findl, MBA

Target Recruit Count: 60

Registration Number: NCT02215330

Locations: 🇦🇹
Oliver Findl, Vienna, Austria

Eplerenone For the Treatment of Chronic Central Serous Chorioretinopathy

Phase 2

Conditions: Central Serous Chorioretinopathy

Interventions: Drug: Eplerenone

First Posted Date: 2014-06-02

Last Posted Date: 2014-06-02

Lead Sponsor: Tel-Aviv Sourasky Medical Center

Target Recruit Count: 30

Registration Number: NCT02153125

Locations: 🇮🇱
Tel Aviv Souraski Medical Center, Tel Aviv, Israel

The Effect of EPLerenone on Ischemia Reperfusion Injury in Human myoCARDium

Not Applicable

Completed

Conditions: Ischemia-reperfusion Injury

Interventions: Drug: Eplerenone

First Posted Date: 2014-04-21

Last Posted Date: 2016-01-12

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 24

Registration Number: NCT02118753

Locations: 🇳🇱
Radboud University Medical Centre, Nijmegen, Gelderland, Netherlands

The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension

Phase 2

Completed

Conditions: Hypertension

Interventions: Drug: Eplerenone
Drug: Amlodipine
Procedure: Microneurography
Procedure: Rhythmic handgrip exercise
Procedure: Sustained hand grip
Procedure: Forearm blood flow
Procedure: Arm cycling exercise
Procedure: Cold Pressor test

First Posted Date: 2013-11-27

Last Posted Date: 2022-03-18

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 14

Registration Number: NCT01996449

Locations: 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy